SLC13A5-IN-1

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

SLC13A5-IN-1是柠檬酸钠协同转运蛋白（SLC13A5）的选择性抑制剂，完全阻断14C-柠檬酸盐的摄取（HepG2细胞中IC50：0.022 μM）。

SLC13A5-IN-1 is a selective inhibitor of sodium-citrate co-transporter (SLC13A5),completely blocks?the uptake of?14C-citrate(IC50 : 0.022 μM in HepG2 cells).(In Vitro):In HepG2/14C-Citrate Uptake Assay，SLC13A5-IN-1 exhibits an IC50 of 0.022 μM . HepG2 cells endogenously express hSLC13A5 transporter which is responsible for the uptake of citrate into these cells. Uptake of 14C-citrate can be completely blocked by SLC13A5-IN-1 and the signal can be competed with unlabelled citrate.In recombinant hSLC3A5/14C-Citrate Uptake Assay, SLC13A5-IN-1 exhibits an IC50 of 0.056 μM . SLC13A5-IN-1 exhibits an IC50 of 100 μM in recombinant Human GlyT2/3H-Glycine Uptake Assay. The human embryonic kidney 293 cells are used that stably over-express the human GlyT2 receptor which is responsible for the uptake of glycine into these cells. Uptake of 3H-glycine can be completely blocked by SLC13A5-IN-1.

SLC13A5-IN-1 exhibits an IC50 of 0.022 μM in HepG2/14C-Citrate Uptake Assay. HepG2 cells endogenously express hSLC13A5 transporter which is responsible for the uptake of citrate into these cells. Uptake of 14C-citrate can be completely blocked by SLC13A5-IN-1 and the signal can be competed with unlabelled citrate. T.SLC13A5-IN-1 exhibits an IC50 of 0.056 μM in recombinant hSLC3A5/14C-Citrate Uptake Assay.SLC13A5-IN-1 exhibits an IC50 of 100 μM in recombinant Human GlyT2/3H-Glycine Uptake Assay. The human embryonic kidney 293 cells are used that stably over-express the human GlyT2 receptor which is responsible for the uptake of glycine into these cells. Uptake of 3H-glycine can be completely blocked by SLC13A5-IN-1.

——

——

Metabolic Enzyme/Protease

SCD

dopamine uptake

——

——

2227548-95-8

461.78

C19H19Cl3N2O3S

>98% (HPLC)

In Vitro:?DMSO : 12.5 mg/mL (27.07 mM)

Clc1ccc(CNC(=O)C2CCN(CC2)S(=O)(=O)c2cc(Cl)cc(Cl)c2)cc1

——

(-20℃)

With Ice Pack

≥ 2 years